- Home
- SCNI vs INM Comparison
SCNI vs INM Comparison
Compare SCNI & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- INM
- Stock Information
- Founded
- SCNI 2003
- INM 1981
- Country
- SCNI Israel
- INM Canada
- Employees
- SCNI N/A
- INM N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- INM Health Care
- Exchange
- SCNI Nasdaq
- INM Nasdaq
- Market Cap
- SCNI 4.6M
- INM 5.1M
- IPO Year
- SCNI N/A
- INM N/A
- Fundamental
- Price
- SCNI $1.37
- INM $2.11
- Analyst Decision
- SCNI
- INM
- Analyst Count
- SCNI 0
- INM 0
- Target Price
- SCNI N/A
- INM N/A
- AVG Volume (30 Days)
- SCNI 95.4K
- INM 127.6K
- Earning Date
- SCNI 11-21-2025
- INM 11-13-2025
- Dividend Yield
- SCNI N/A
- INM N/A
- EPS Growth
- SCNI N/A
- INM N/A
- EPS
- SCNI 0.26
- INM N/A
- Revenue
- SCNI $1,147,000.00
- INM $4,942,633.00
- Revenue This Year
- SCNI N/A
- INM N/A
- Revenue Next Year
- SCNI N/A
- INM N/A
- P/E Ratio
- SCNI $5.20
- INM N/A
- Revenue Growth
- SCNI 303.87
- INM 7.50
- 52 Week Low
- SCNI $1.20
- INM $1.72
- 52 Week High
- SCNI $6.18
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- SCNI 45.19
- INM 42.17
- Support Level
- SCNI $1.32
- INM $2.17
- Resistance Level
- SCNI $1.63
- INM $2.50
- Average True Range (ATR)
- SCNI 0.11
- INM 0.13
- MACD
- SCNI 0.01
- INM -0.00
- Stochastic Oscillator
- SCNI 38.37
- INM 15.22
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.